Tumor parameters, clinical and pathological responses, medical management, and survival through time on 710 operable breast cancers

Medical Oncology

Volumn 22, Issue 3, 2005, Pages 233-240

  Abrial, C ^a,b   Mouret Reynier, M A ^a,c   Amat, S ^a   Sillet Bach, I ^d   Bougnoux, P ^e   Delva, R ^f   Cure, H ^a,c   Dauplat, J ^a,c   Penault Llorca, F ^a,c   Chollet, P ^a,c  

^a CENTRE JEAN PERRIN   (France)

^b INSERM   (France)

^c UNIVERSITÉ CLERMONT AUVERGNE   (France)

^d Centre Hospitalier General   (France)

^e CHU BRETONNEAU   (France)

^f CENTRE PAUL PAPIN   (France)

Author keywords

Breast cancer; Clinical and pathological responses; Survival

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; HORMONE RECEPTOR; METHOTREXATE; NAVELBINE; PACLITAXEL; PIRARUBICIN; TAMOXIFEN; VINCRISTINE;

ADJUVANT CHEMOTHERAPY; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MENOPAUSE; PATIENT CODING; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HISTORY, MEDIEVAL; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; PROGNOSIS; TREATMENT OUTCOME;

EID: 23844495196     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1385/MO:22:3:233     Document Type: Article

References (10)

1. Buchholz T, et al. Neoadjuvant chemotherapy for breast carcinoma: multidisciplinary considerations of benefits and risks. Cancer 2003;98(6):1150-1160.
2. Brain E, et al. Long-term prognostic and predictive factors in 107 stage II/III breast cancer patients treated with anthracycline-based neoadjuvant chemotherapy. Br J Cancer 1997;77:1360-1367.
3. Chollet P, et al. Clinical and pathological response to primary chemotherapy in inoperable breast cancer. Eur J Cancer 1997;33(6):862-866.
4. Bonadonna G, et al. Primary chemotherapy in operable breast cancer; eight-year experience at the Milan Cancer Institute. J Clin Oncol 1998;16:93-100.
5. Pierga J-Y, et al. Prognostic value of persistent node involvement after neoadjuvant chemotherapy in patients with operable breast cancer. Br J Cancer 2000;83(11):1480-1487.
6. Van Praagh I, et al. Efficacy of a primary regimen combining vinorelbine, epirubicin and methotrexate (VEM) as neoadjuvant treatment in 89 patients with operable breast cancer. The Oncologist 2002;7:418-423.
7. Amat S, et al. Neoadjuvant docetaxel for operable breast cancer induces a high pathological response and breast-conservation rate. Br J Cancer 2003;88(9):1339-1345.
8. Chevallier B, et al. Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate. Am J Clin Oncol 1993;16:223-228.
9. Kaplan EL, Meier P. Non parametric estimation from incomplete observation. J Am Stat Assoc 1957;53:457-471.
10. Amat S, et al. Scarff-Bloom-Richardson (SBR) grading: a pleiotropic marker of chemosensitivity in invasive ductal breast carcinomas treated by neoadjuvant chemotherapy. Int J Oncol 2002;20:791-796.